Should the US allow prescription drug reimports from Canada?
As a result of public outrage over lower prescription drug prices in Canada, Congress passed legislation that would allow these drugs to be imported into the US. The lower Canadian prices reflect price regulation. Opponents of allowing these imports have argued that the US will import Canadian price controls and that profits of pharmaceutical companies will be hurt. In this paper, a model is developed in which a good sold in the foreign country is subject to a negotiated price which is determined in a Nash bargaining game. When imports back into the home country are allowed, this negotiated price also becomes the domestic price. This causes the home firm to make fewer price concession in the Nash bargaining game. Home firm profits are found to rise under the reimport regime for both of the demand functions analyzed in this paper.
Pecorino
Paul
P
Department of Economics, Finance and Legal Studies, University of Alabama, Tuscaloosa 35487-0224, USA. ppecorin@cba.ua.edu
D002170:Canada; D003132:Commerce / Q000191:economics* / Q000331:legislation & jurisprudence; D003363:Cost Control / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics; D006291:Health Policy / Q000191:economics / Q000331:legislation & jurisprudence; D006301:Health Services Needs and Demand / Q000191:economics*; D006801:Humans; D007391:International Cooperation; D017059:Models, Econometric; D004364:Pharmaceutical Preparations / Q000191:economics* / Q000600:supply & distribution*; D011306:Prescription Fees / Q000331:legislation & jurisprudence*; D014481:United States
D004364:Pharmaceutical Preparations